Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.

Events Timeline

(ET)

2026-02-24

08:10:00

Aktis Oncology's AKY-1189 Receives FDA Fast Track Designation

2026-01-12 (ET)

2026-01-12

11:20:00

Aktis Oncology Shares Surge Over 5% on First Trading Day

2026-01-09 (ET)

2026-01-09

11:20:00

Aktis Oncology Prices IPO at $18 Per Share

2026-01-09

06:20:00

IPO Priced at High End of $16.00-$18.00 Range

2026-01-05 (ET)

2026-01-05

13:30:00

JPMorgan, BofA, and Others Jointly Manage New Stock Offering

News

9.0

02-24Newsfilter

FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment

8.5

02-04renaissancecapital

2026 IPO Market Starts Steadily with $2.6 Billion Raised

8.5

02-04renaissancecapital

2026 IPO Market Starts Steadily with $2.6 Billion Raised

6.0

02-03Benzinga

Wall Street Analysts Adjust Ratings

5.0

01-13NASDAQ.COM

Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment

8.5

01-13Globenewswire

Aktis Oncology Closes Upsized IPO Raising $365.4 Million

4 Analyst Rating

Wall Street analysts forecast AKTS stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

31.67

High

34.00

Current: 0.000

Low

30.00

Averages

31.67

High

34.00

JPMorgan

Overweight

initiated

$30

AI Analysis

2026-02-03

Reason

JPMorgan

Price Target

$30

AI Analysis

2026-02-03

initiated

Overweight

Reason

JPMorgan initiated coverage of Aktis Oncology with an Overweight rating and $30 price target. The company has an "attractive" platform for developing radiopharmaceutical therapies, a novel means of delivering targeted radiation for cancer, the analyst tells investors in a research note. The firm sees radiopharmaceutical therapy modality "taking off" in the coming years and thinks Aktis is "entering at a sweet spot" where it can develop "first-in-class products in a relatively open field."

TD Cowen

Tyler Van Buren

Buy

initiated

2026-02-03

Reason

TD Cowen

Tyler Van Buren

Price Target

2026-02-03

initiated

Buy

Reason

TD Cowen analyst Tyler Van Buren initiated coverage of Aktis Oncology with a Buy rating and no price target. The firm says the company's miniprotein technology has the opportunity to access radiotherapy "white space." AKY-1189 and AKY-2519 have demonstrated durable tumor retention with minimal healthy tissue exposure, which de-risks the upcoming studies, the analyst tells investors in a research note. TD estimates over $5B in combined 2035 sales.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AKTS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Aktis Oncology Inc (AKTS.O) is -0.02, compared to its 5-year average forward P/E of -5.38. For a more detailed relative valuation and DCF analysis to assess Aktis Oncology Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.38

Current PE

-0.02

Overvalued PE

-0.43

Undervalued PE

-10.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.22

Undervalued EV/EBITDA

-9.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.46

Current PS

0.02

Overvalued PS

19.81

Undervalued PS

-0.90

Financials

AI Analysis

Annual

Quarterly

Whales Holding AKTS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Aktis Oncology Inc (AKTS) stock price today?

The current price of AKTS is 20 USD — it has decreased -0.65

What is Aktis Oncology Inc (AKTS)'s business?

What is the price predicton of AKTS Stock?

Wall Street analysts forecast AKTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is31.67 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aktis Oncology Inc (AKTS)'s revenue for the last quarter?

Aktis Oncology Inc revenue for the last quarter amounts to 9.03M USD, increased 28.92

What is Aktis Oncology Inc (AKTS)'s earnings per share (EPS) for the last quarter?

Aktis Oncology Inc. EPS for the last quarter amounts to -0.04 USD, decreased -85.71

How many employees does Aktis Oncology Inc (AKTS). have?

Aktis Oncology Inc (AKTS) has 117 emplpoyees as of March 02 2026.

What is Aktis Oncology Inc (AKTS) market cap?

Today AKTS has the market capitalization of 1.06B USD.

AKTS Overview

AKTS Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding AKTS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Aktis Oncology Inc (AKTS) stock price today?

What is Aktis Oncology Inc (AKTS)'s business?

What is the price predicton of AKTS Stock?

What is Aktis Oncology Inc (AKTS)'s revenue for the last quarter?

What is Aktis Oncology Inc (AKTS)'s earnings per share (EPS) for the last quarter?

How many employees does Aktis Oncology Inc (AKTS). have?

What is Aktis Oncology Inc (AKTS) market cap?